As per MRFR analysis, the UK Geographic Atrophy GA Market Size was estimated at 1.62 (USD Billion) in 2024.The UK Geographic Atrophy GA Market Industry is expected to grow from 1.75(USD Billion) in 2025 to 3 (USD Billion) by 2035. The UK Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 5.022% during the forecast period (2025 - 2035).
The UK Geographic Atrophy (GA) market is witnessing significant trends driven by an aging population and rising prevalence of retinal diseases. As the UK’s demographics shift, with a growing percentage of older adults, there is an increasing demand for treatments and management of age-related macular degeneration (AMD) and GA. The UK healthcare sector is actively focusing on innovative therapies, highlighting the importance of research and development.
The National Health Service (NHS) recognizes the need for improved treatment pathways for conditions like Geographic Atrophy, thereby boosting the market for novel therapeutic approaches. Moreover, advancements in diagnostic technologies are creating new opportunities in the UK GA market. The utilization of high-resolution imaging techniques and artificial intelligence in ophthalmology is facilitating early diagnosis and better monitoring of GA progression.
This has the potential to enhance patient outcomes and open up avenues for personalized treatment plans. Additionally, regulatory support for the approval of new treatments is encouraging pharmaceutical companies to invest in the research of GA therapeutics, spurring market growth. In recent times, there has been a noticeable trend toward patient-centered care.
Healthcare providers in the UK are emphasizing the importance of patient education and involvement in decision-making regarding their treatment options. This shift reflects a broader movement within the healthcare system that values the patient’s perspective. By addressing the growing need for awareness and support regarding Geographic Atrophy, stakeholders can better meet patient needs and capture the evolving market potential while ensuring accessibility and affordability of treatments. The combination of these trends is shaping the future landscape of the Geographic Atrophy market in the UK.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
The UK Geographic Atrophy GA Market Industry is significantly driven by the increasing prevalence of age-related macular degeneration (AMD). Reports indicate that AMD affects around 600,000 individuals in the UK, with projections suggesting this number could double by 2050, as the population ages. The National Health Service (NHS) has recognized AMD as a leading cause of blindness in people over 50, and this population is rapidly increasing due to longevity trends.
Consequently, this rising patient demographic is expected to drive the demand for Geographic Atrophy treatments. Additionally, initiatives from organizations such as the Royal National Institute of Blind People (RNIB) emphasize awareness and research into AMD, further fueling the need for effective therapeutic interventions and expanding the market for Geographic Atrophy in the UK.
The UK Geographic Atrophy GA Market Industry is witnessing significant growth driven by advancements in Research and Development in the field of ophthalmology. Notably, an increase in funding for projects targeting retinal diseases has been observed, with UK Research and Innovation (UKRI) allocating substantial grants specifically for eye health research, reflecting a commitment to combat conditions like Geographic Atrophy.
Furthermore, several pharmaceutical companies, such as Novartis and Roche, are developing innovative therapies that target the underlying causes of Geographic Atrophy, thus expected to launch within the next few years. This surge in innovative treatments is projected to bring new hope to patients while driving market growth significantly.
Rising awareness regarding Geographic Atrophy and its implications is a crucial driver for the UK Geographic Atrophy GA Market Industry. Public health campaigns led by organizations including the NHS and the Macular Society have heightened awareness of the symptoms and risks associated with macular degeneration, encouraging more individuals to seek early screening.
According to surveys conducted by these organizations, awareness of AMD has increased by over 25% in the last five years, promoting early diagnosis and treatment. Through the incorporation of periodic eye examinations into routine check-ups, the UK hopes to identify vulnerable populations and, subsequently, increase the number of patients suffering from Geographic Atrophy.
The UK Geographic Atrophy GA Market significantly focuses on age groups as a primary segmentation factor, showcasing important insights, particularly in the demographic categories of individuals above 60 Years and above 75 Years. As populations in the UK continue to age, there is an increasing prevalence of age-related eye diseases such as Geographic Atrophy, which can lead to substantial vision impairment. The impact of this condition is particularly notable among individuals in the 60 years category, who experience a higher risk and greater incidence of the disease.
This demographic not only represents a majority holding in terms of total patients affected but is also where most clinical focus and healthcare resources are directed, driving innovation in treatment and management practices. Furthermore, individuals 75 Years are often more susceptible, as the likelihood of developing Geographic Atrophy increases with age. This age group typically experiences a complex interplay of ocular health issues, making them a critical segment for targeted healthcare interventions and advancements in therapies.
The significant growth of this market segment can be attributed to several factors, such as an increasing aging population, advancements in diagnostic technologies, and an enhanced understanding of Geographic Atrophy. Additionally, public awareness campaigns aimed at educating the elderly about eye health contribute to early detection and intervention, underscoring the relevance of these age categories in shaping the overall market dynamics.
In the UK, with initiatives derived from the National Health Service aimed at improving outcomes for older adults, there is an evident push towards research and development targeting treatments that alleviate the burden of vision loss in these age groups. Given the correlation between an aging population and the rise in eye health issues, the focus on these age demographics in the UK Geographic Atrophy GA Market underscores their importance not only from a clinical perspective but also as a solid market opportunity that perpetuates ongoing research, treatment development, and patient care improvement.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
The Diagnosis segment of the UK Geographic Atrophy GA Market is crucial for early detection and management of this retinal disease, which is notorious for leading to significant vision loss among the elderly population. Advanced imaging techniques such as Fundus Autofluorescence are pivotal for detecting changes in the retinal structure, allowing for effective monitoring of disease progression. Optical Coherence Tomography Angiography plays a significant role by providing detailed views of the retinal and choroidal vasculature without invasive procedures, enhancing the accuracy of diagnoses.
Furthermore, Multifocal Electroretinography is essential for evaluating retinal function, providing invaluable data on how the disease impacts visual pathways. The increasing prevalence of Geographic Atrophy, particularly in the aging UK population, drives the demand for these diagnostic modalities. Enhanced technology and improved imaging techniques also present unique opportunities for further market growth, despite challenges related to cost and access to high-quality devices in certain healthcare settings. As health authorities in the UK focus on managing chronic ocular conditions, the emphasis on accurate diagnostic methods remains a priority in the ongoing evolution of the UK Geographic Atrophy GA Market.
The Therapeutic Agents Clinical Phase within the UK Geographic Atrophy GA Market showcases significant progress and evolution, reflecting the heightened focus on combating this condition that leads to irreversible vision loss. The segment includes various stages, each playing a critical role in the development of innovative treatment options. Late-candidates often represent the culmination of extensive Research and Development efforts, with the potential to provide effective therapies for patients suffering from Geographic Atrophy.
Phase II and Phase I studies serve to further refine treatment protocols, offering insights into safety and efficacy as they progress toward larger-scale testing. The Pre-Clinical Stage involves rigorous lab research, laying the groundwork for actual clinical trials, while Discovery Candidates symbolize the early identification of novel compounds that could revolutionize treatment approaches.
Each of these stages not only contributes to the advancement of the UK Geographic Atrophy GA Market industry but also reflects the commitment to addressing unmet medical needs in the aging population. This segment is essential for market growth and sets the foundation for future innovations that may lead to better patient outcomes. Overall, these combined efforts signify an optimistic trajectory for therapeutic advancements in this critical area.
The UK Geographic Atrophy (GA) Market is increasingly becoming competitive as the prevalence of age-related macular degeneration continues to rise, necessitating the development of innovative therapies. This condition leads to irreversible vision loss and poses significant health challenges, prompting pharmaceutical companies to invest in research and development of effective treatment options. The competitive landscape is characterized by a combination of established players and new entrants vying for market share through unique product offerings, strategic collaborations, and geographical expansions.
As regulatory frameworks evolve and patient populations grow, the strategies employed by these companies will play a critical role in shaping the future of the GA market in the UK. Horizon Therapeutics has established a notable presence in the UK Geographic Atrophy Market by leveraging its specialization in rare and underserved diseases. The company's product development emphasizes a strong commitment to addressing the unmet medical needs of patients suffering from GA.
Horizon Therapeutics is recognized for its strategic research initiatives, which aim to advance innovative therapies for ocular diseases, reinforcing its position within this niche segment. The company’s strengths lie in its ability to forge collaborations with research institutions, which enhances its capacity for innovation. Additionally, Horizon Therapeutics maintains a robust pipeline of potential therapies specific to GA, making it well-positioned to address upcoming challenges and capitalize on emerging opportunities in the market.
Apellis Pharmaceuticals is another key player in the UK Geographic Atrophy Market, known for its commitment to delivering transformative therapies designed to improve patient outcomes. The company has developed cutting-edge treatments focused on complement inhibition, a novel approach to managing GA. Apellis Pharmaceuticals has successfully secured a foothold in the UK through its flagship product aimed at addressing the underlying pathophysiology of GA.
The company has strategically engaged in partnerships and collaborations aimed at enhancing research capabilities and expanding its market reach. With a focus on innovation, Apellis Pharmaceuticals continues to strengthen its product offerings and optimize its presence in the GA landscape. Mergers and acquisitions have also played a role in boosting its capabilities, allowing the company to advance its pipeline and broaden its competitive advantage within the UK market.
The UK Geographic Atrophy (GA) market has seen significant developments in recent months. Horizon Therapeutics and Apellis Pharmaceuticals are actively involved in advancing therapies aimed at treating GA, with Apellis continuing to gain traction for its innovative complement inhibition approach. Furthermore, Novartis has recently expanded its research footprint in the UK to enhance its ocular portfolio related to retinal diseases.
In terms of mergers and acquisitions, there have been no widely reported engagements involving the companies of specific interest in the UK market. Growth in market valuation has been observed, particularly with companies such as Regeneron Pharmaceuticals and Sobi, which are focusing on expanding their Research and Development efforts in the GA domain. The UK has observed a rising prevalence of GA, prompting a greater emphasis on early diagnosis and potential therapies. Over the past few years, developments in gene therapy through Iovance Biotherapeutics and others significant attention in the research environments of UK healthcare institutions. These advancements contribute to a dynamic and evolving landscape for Geographic Atrophy treatment solutions in the UK.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.62(USD Billion) |
| MARKET SIZE 2024 | 1.75(USD Billion) |
| MARKET SIZE 2035 | 3.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.022% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Horizon Therapeutics, Apellis Pharmaceuticals, Iovance Biotherapeutics, Ophthotech, Novartis, Bayer, Retinagenix, Sobi, AstraZeneca, Zymeworks, Eyenovia, Genentech, Regeneron Pharmaceuticals, MediCane Health, Santen |
| SEGMENTS COVERED | Age Group, Diagnosis, Therapeutic Agents Clinical Phase |
| KEY MARKET OPPORTUNITIES | Emerging gene therapies, Increased awareness campaigns, Advanced diagnostic technologies, Strategic partnerships for research, Growing elderly population |
| KEY MARKET DYNAMICS | Aging population increasing incidence, Limited treatment options available, Rising healthcare expenditure in ophthalmology, Growing awareness and early diagnosis, Advancements in clinical trials and research |
| COUNTRIES COVERED | UK |
Frequently Asked Questions (FAQ) :
The UK Geographic Atrophy GA Market is expected to be valued at 1.75 billion USD in 2024.
By 2035, the overall market is projected to reach a value of 3.0 billion USD.
The market is expected to grow at a CAGR of 5.022% during the forecast period from 2025 to 2035.
The age group above 60 years holds a significant market share, with a value of 1.05 billion USD in 2024.
For the above 75 years age group, the market is valued at 0.7 billion USD in 2024.
Major players in the market include Horizon Therapeutics, Apellis Pharmaceuticals, and Novartis among others.
By 2035, the market value for the above 60 years age group is anticipated to reach 1.75 billion USD.
The expected market value for the above 75 years age group is projected at 1.25 billion USD in 2035.
The primary growth drivers include increasing prevalence of age-related diseases and advancements in treatment options.
Current global trends and conflicts may impact supply chains and regulatory environments affecting market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
